Clinical trials for coronavirus vaccine begin at University Medical Center in Germany
The University Medical Center Hamburg-Eppendorf in Germany begins dosing healthy adult participants in a Phase I clinical trial of Covid-19 vaccine candidate.
The aim of the study is to assess the safety and tolerability of the candidate vaccine MVA-SARS-2-S against COVID-19 and to characterize its immunogenicity.
During the Phase I trial, approximately 30 participants aged 18 to 55 will be enrolled.
In this Phase I first-in-human clinical trial, healthy volunteers in two different dose cohorts will be vaccinated twice with the candidate vaccine.
Healthy male and female adults without clinically significant health problems who agree to comply with the applicable contraceptive requirements of the protocol can be included into this study.
The trial is planning to complete on May 2021.
The location of the trial is CTC North GmbH & Co KG at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany.
Among the sponsors and collaborators are the Universitätsklinikum Hamburg-Eppendorf, German Center for Infection Research, Philipps University Marburg Medical Center and Ludwig-Maximilians - University of Munich.
